First Community (FCCO) EPS Estimated At $0.37; Intercept (ICPT) Sentiment Is 1.15

June 22, 2018 - By Vivian Currie

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Logo

Analysts expect First Community Corporation (NASDAQ:FCCO) to report $0.37 EPS on July, 18.They anticipate $0.13 EPS change or 54.17% from last quarter’s $0.24 EPS. FCCO’s profit would be $2.81M giving it 16.25 P/E if the $0.37 EPS is correct. After having $0.35 EPS previously, First Community Corporation’s analysts see 5.71% EPS growth. The stock decreased 5.13% or $1.3 during the last trading session, reaching $24.05. About 52,178 shares traded or 135.09% up from the average. First Community Corporation (NASDAQ:FCCO) has risen 23.10% since June 22, 2017 and is uptrending. It has outperformed by 10.53% the S&P500. Some Historical FCCO News: 10/05/2018 – PG&E Signs on First Community Solar Project for Regional Renewable Choice Program; 17/04/2018 First Community Solar Plus Storage Project in Massachusetts Dedicated Today; 10/05/2018 – ForeFront Power to Develop First Community Solar Project for PG&E’s Regional Renewable Choice Program; 19/04/2018 – DJ First Community Corporation, Inst Holders, 1Q 2018 (FCCT); 18/04/2018 – FIRST COMMUNITY CORP FCCO.O SETS QUARTERLY CASH DIVIDEND OF $0.10/SHR; 19/04/2018 – DJ First Community Corporation, Inst Holders, 1Q 2018 (FCCO); 24/04/2018 – The New Home Company Announces Model Home Grand Opening for First Community in San Diego; 18/04/2018 – First Community (SC) 1Q EPS 35c

Intercept Inc (ICPT) investors sentiment decreased to 1.15 in 2018 Q1. It’s down -0.16, from 1.31 in 2017Q4. The ratio fall, as 68 funds opened new and increased positions, while 59 decreased and sold their equity positions in Intercept Inc. The funds in our database now own: 18.85 million shares, up from 17.97 million shares in 2017Q4. Also, the number of funds holding Intercept Inc in top ten positions was flat from 1 to 1 for the same number . Sold All: 24 Reduced: 35 Increased: 48 New Position: 20.

More notable recent Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news were published by: Seekingalpha.com which released: “Intercept Pharmaceuticals: Buyout Speculation Stokes Shares” on June 12, 2018, also Seekingalpha.com with their article: “Intercept And Obeticholic Acid Therapy: Discerning Scientific Facts From Fallacies On Cholestatic Liver Diseases” published on June 12, 2018, Fool.com published: “Why Viking Therapeutics Stock Is On Fire Today” on May 31, 2018. More interesting news about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) were released by: Fool.com and their article: “3 Top Biotech Stocks to Buy Right Now” published on June 18, 2018 as well as Seekingalpha.com‘s news article titled: “Intercept’s Obeticholic Acid Therapy And NASH: The Scientific Truth Is That Every Cloud Has A Silver Lining” with publication date: June 13, 2018.

The stock decreased 1.19% or $1.01 during the last trading session, reaching $84.11. About 335,846 shares traded. Intercept Pharmaceuticals, Inc. (ICPT) has declined 38.34% since June 22, 2017 and is downtrending. It has underperformed by 50.91% the S&P500. Some Historical ICPT News: 05/04/2018 – Intercept Pharmaceuticals Announces Pricing of Upsized $250 Million Public Offering and Concurrent Private Placement of Common; 04/04/2018 – INTERCEPT – EXPECTS NET SALES OF OCALIVA FOR QTR ENDED MARCH 31, TO BE SLIGHTLY LOWER THAN NET SALES OF OCALIVA FOR QTR ENDED DEC 31, 2017; 31/05/2018 – Intercept Lead in Fatty Liver Disease Threatened by Upstart; 02/05/2018 – Intercept Pharma Presenting at UBS Conference May 21; 11/05/2018 – Elk Creek Partners Buys New 1.2% Position in Intercept Pharma; 04/04/2018 – ICPT SEES 1Q TOTAL OCALIVA PRESCRIPTIONS FILLED CONSISTENT W/4Q; 23/03/2018 – Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress™ 2018; 08/05/2018 – INTERCEPT PHARMA 1Q LOSS/SHR $3.22, EST. LOSS/SHR $3.31; 08/05/2018 – Intercept Pharmaceuticals 1Q Loss/Shr $3.22; 05/04/2018 – INTERCEPT PHARMACEUTICALS REPORTS PRICING OF UPSIZED $250M

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $2.49 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Sarissa Capital Management Lp holds 9.04% of its portfolio in Intercept Pharmaceuticals, Inc. for 635,300 shares. Elk Creek Partners Llc owns 348,454 shares or 1.25% of their US portfolio. Moreover, Altrinsic Global Advisors Llc has 0.93% invested in the company for 375,223 shares. The Switzerland-based Bb Biotech Ag has invested 0.93% in the stock. Opus Point Partners Management Llc, a New York-based fund reported 4,496 shares.

Analysts await Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report earnings on July, 30. They expect $-2.94 EPS, up 15.03% or $0.52 from last year’s $-3.46 per share. After $-3.22 actual EPS reported by Intercept Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -8.70% EPS growth.

Investors sentiment decreased to 2.33 in Q1 2018. Its down 0.67, from 3 in 2017Q4. It dived, as 1 investors sold First Community Corporation shares while 8 reduced holdings. 5 funds opened positions while 16 raised stakes. 3.01 million shares or 0.18% less from 3.02 million shares in 2017Q4 were reported. Mendon Capital holds 290,894 shares or 0.6% of its portfolio. Cutler Mgmt Ltd Liability Com accumulated 15,000 shares. Savings Bank Of New York Mellon holds 9,843 shares. Germany-based Deutsche Bank Ag has invested 0% in First Community Corporation (NASDAQ:FCCO). 34,145 were accumulated by Dimensional Fund Advisors L P. Vanguard Gp Inc invested in 0% or 129,957 shares. Moreover, Blair William And Il has 0% invested in First Community Corporation (NASDAQ:FCCO) for 19,224 shares. Rbf Capital Ltd Liability holds 70,000 shares or 0.19% of its portfolio. Morgan Stanley holds 0% of its portfolio in First Community Corporation (NASDAQ:FCCO) for 3,827 shares. Wellington Mgmt Gru Llp stated it has 422,301 shares. Rmb Capital Mgmt Ltd Company holds 392,763 shares or 0.23% of its portfolio. Banc Funds Ltd Liability Company stated it has 0.26% of its portfolio in First Community Corporation (NASDAQ:FCCO). Alliancebernstein Ltd Partnership holds 14,014 shares. 4,749 were reported by Blackrock. Tower Research Cap Limited Liability Com (Trc) invested 0% in First Community Corporation (NASDAQ:FCCO).

Since February 13, 2018, it had 0 insider buys, and 3 insider sales for $114,906 activity. CRAPPS MICHAEL C also sold $29,026 worth of First Community Corporation (NASDAQ:FCCO) shares. BOGAN RICHARD K sold 3,000 shares worth $64,800. The insider EASTER ANITA B sold $21,080.

First Community Corporation operates as the bank holding firm for First Community Bank which offers various commercial and retail banking services and products to small-to-medium sized businesses, professional concerns, and individuals. The company has market cap of $182.80 million. The firm operates through four divisions: Commercial and Retail Banking, Mortgage Banking, Investment Advisory and Non-Deposit, and Corporate. It has a 25.78 P/E ratio. The Company’s deposit products include demand deposit accounts, checking accounts, NOW accounts, and savings accounts, as well as other time deposits, such as daily money market accounts and longer-term certificates of deposits.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>